Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study)

Haruko Shima, MD PhD, Akiko Kada, MPH, Akihiko Tanizawa, MD PhD, Yuki Yuza, MD PhD, Akihiro Watanabe, Masaki Ito, MD, Hideko Uryu, Katsuyoshi Koh, MD, Chihaya Imai, MD PhD, Nao Yoshida, MD PhD, Yuhki Koga, MD, Naoto Fujita, MD PhD, Akiko M Saito, MD PhD, Souichi Adachi, MD PhD, Eiichi Ishii, MD PhD, Hiroyuki Shimada, MD PhD

Blood (2019) 134 (Supplement_1): 25.

https://doi.org/10.1182/blood-2019-122623

Published: 2019

Journal Articles

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma

Lekha Mikkilineni, MD, Elisabet E. Manasanch, MD, Norris Lam, BS, Danielle Vanasse, BS, Jennifer N. Brudno, MD, Irina Maric, MD MSci, Jeremy J. Rose, MS, Maryalice Stetler-Stevenson, MD PhD, Hao-Wei Wang, MD PhD, Constance M. Yuan, MD PhD, David F. Stroncek, MD, Jennifer Mann, CRNP, Micaela Ganadan, BSN, RN, Rashmika Patel, Nathan Trinklein, PhD, Ben Buelow, MD PhD, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2019) 134 (Supplement_1): 3230.

https://doi.org/10.1182/blood-2019-129088

Published: 2019

Journal Articles

Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas

Jun Zhu, MD PhD, Junning Cao, MD, Lugui Qiu, MD PhD, Junyuan Qi, MD, Yuqin Song, MD PhD, Meifeng Tu, MD PhD, Dongmei Ji, MD PhD, Weina Shen, MD, Mingyuan Sun, MD, Ye Hua, MD, Chen Yang, MD, Chen Yu, MD, Jian Wang, PhD, Guangxiu Dai, PhD, Weiguo Su, PhD

Blood (2018) 132 (Supplement 1): 5324.

https://doi.org/10.1182/blood-2018-99-111648

Published: 2018

Journal Articles

Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study

Yuqin Song, MD PhD, Quanli Gao, MD, Huilai Zhang, PhD, Lei Fan, MD PhD, Jianfeng Zhou, PhD, Dehui Zou, MD, Wei Li, MD, Haiyan Yang, PhD, Ting Liu, MD, Quanshun Wang, MD PhD, Fangfang Lv, MD, Yu Yang, MD, Haiyi Guo, MD, Liudi Yang, MD, Rebecca Elstrom, MD, Jane Huang, MD, William Novotny, MD, Vivian Wei, PhD, Jun Zhu, MD PhD

Blood (2018) 132 (Supplement 1): 682.

https://doi.org/10.1182/blood-2018-99-117848

Published: 2018

Journal Articles

Improving Treatment Related Mortality over Time - Data from the Non-Observational Trial on Autologous Stem Cell Transplantation in Systemic Sclerosis By the EBMT Autoimmune Diseases Working Party (ADWP)

Dominique Farge, PhD MD, John A Snowden, MD PhD, Manuela Badoglio, Myriam Labopin, MD, Hans Ulrich Scherer, MD PhD, Nicoletta Del Papa, PhD MD, Lothar Kanz, Marc Schmalzing, MD, Thierry Martin, MD PhD, Montserrat Rovira, MD, Thomas Daikeler, MD PhD, Gregory Pugnet, MD PhD, Joerg Henes, MD PhD

Blood (2018) 132 (Supplement 1): 3431.

https://doi.org/10.1182/blood-2018-99-116602

Published: 2018

Journal Articles

Responses and Cardiotoxicity with R-CDOP and R-CHOP Observed in Frontline Therapy for Patients with Primary Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Randomized Phase-IV Study from Multiple Centers in China

Lili Feng, MD PhD, Xiaoxia Chu, Hongguo Zhao, MD, Yili Wang, Jie Li, Ying Li, MD, Xuehong Ran, Jie Min, Lingyan Zhang, MD, Hongzhi Xu, Jingxia Wang, Ling Wang, Yunliang Hao, Ruirong Xu, Juan Fan, MD, Lei Wang, Xin Wang, MD PhD

Blood (2018) 132 (Supplement 1): 2960.

https://doi.org/10.1182/blood-2018-99-116295

Published: 2018

Journal Articles

Characterization of Cardiovascular Adverse Events and B-Type Natriuretic Peptide Levels in Patients with Multiple Myeloma Who Are Treated with Carfilzomib

Hang Quach, MDFRACP,FRCPA,MBBS, Khue Minh Nguyen, Matthew Ku, MBBS, FRACP, FRCPA, Ali Bazargan, MBBS FRACP FRCPA, Robin J Filshie, PhDFRACP,FRCPA, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Lisa Catherine Demosthenous, MPH, BSN, David Prior, MBBS FRACP PhD

Blood (2018) 132 (Supplement 1): 1956.

https://doi.org/10.1182/blood-2018-99-113802

Published: 2018

Journal Articles

Creatine Kinase Pathway Inhibition Alters GSK3 and WNT Signaling in EVI1-Positive Acute Myeloid Leukemia

Lina Benajiba, Gabriela Alexe, Olivier Hermine, MD PhD, Michael Hemann, Alexandre Puissant, Kimberly Stegmaier, MD

Blood (2017) 130 (Supplement 1): 1191.

https://doi.org/10.1182/blood.V130.Suppl_1.1191.1191

Published: 2017

Journal Articles

Preclinical Investigation of a Potent Geranylgeranyl Diphosphate Synthase Inhibitor

Staci L. Haney, PhD, Yashpal S. Chhonker, PhD, Michelle L. Varney, MS, Geoffrey A. Talmon, MD, Daryl J. Murry, PharmD, Sarah A. Holstein, MD PhD

Blood (2017) 130 (Supplement 1): 4625.

https://doi.org/10.1182/blood.V130.Suppl_1.4625.4625

Published: 2017

Journal Articles

Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study

Carlo Gambacorti-Passerini, MD, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin-Seok Ahn, Joseph T. Beck, William Jeffrey Edenfield, Yuankai Shi, Matthew Taylor, Kenji Tamura, Brian A. Van Tine, Shang-Ju Wu, MD, PhD, Jolanda Paolini, Sherry Li, Tae Min Kim

Blood (2017) 130 (Supplement 1): 4128.

https://doi.org/10.1182/blood.V130.Suppl_1.4128.4128

Published: 2017

Journal Articles

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Aaron T. Gerds, MDMS, Tetsuzo Tauchi, MD, Ellen K. Ritchie, MD, Michael W. Deininger, MD PhD, Catriona HM Jamieson, MD PhD, Ruben Mesa, MD FACP, Mark Lawrence Heaney, MD PhD, Norio Komatsu, MD PhD, Hironobu Minami, MD PhD, M. Naveed Shaik, PhD, Xiaoxi Zhang, PhD, Christine DiRienzo, PhD, Mirjana Zeremski, MD, Geoffrey Chan, MD, Moshe Talpaz, MD

Blood (2017) 130 (Supplement 1): 258.

https://doi.org/10.1182/blood.V130.Suppl_1.258.258

Published: 2017

Journal Articles

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Steven M. Horwitz, MD, Mehdi Hamadani, MD, Michelle A. Fanale, MD, Jay Feingold, MD PhD, Alexander I Spira, MD, Paul A Fields, MD PhD, Tobias Menne, MD PhD, Anand Karnad, MD, Alison J. Moskowitz, MD, Catherine Hildyard, MRCP, BA, Shui He, PhD, Joseph Boni, PhD, Graham Collins, MD PhD

Blood (2017) 130 (Supplement 1): 1510.

https://doi.org/10.1182/blood.V130.Suppl_1.1510.1510

Published: 2017

Journal Articles

Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia

Alexandre Puissant, PhD, Nina Fenouille, PhD, Christopher F. Bassil, BA, Issam Ben-Sahra, PhD, Lina Benajiba, Gabriela Alexe, PhD, Azucena Ramos, Yana Pikman, MD, Michael R. Burgess, MD PhD, Qing Li, MD PhD, Frederic Luciano, PhD, Patrick Auberger, PhD, Ilene Galinsky, MSN, ANPc, Daniel J. DeAngelo, MD PhD, Richard M. Stone, MD, Archibald S. Perkins, MD PhD, Kevin Shannon, MD, Michael T. Hemann, PhD, Kimberly Stegmaier, MD

Blood (2016) 128 (22): 523.

https://doi.org/10.1182/blood.V128.22.523.523

Published: 2016

Journal Articles

Identification of CKMT1B As a New Target in EVI1-Positive AML

Alexandre Puissant, PhD, Nina Fenouille, PhD, Christopher F. Bassil, BA, Issam Ben-Sahra, PhD, Gabriela Alexe, PhD, Lina Benajiba, Azucena Ramos, Yana Pikman, MD, Michael R. Burgess, MD PhD, Ilene Galinsky, ANP, Daniel J. DeAngelo, MD PhD, Richard M. Stone, MD, Kevin Shannon, MD, Michael T. Hemann, PhD, Kimberly Stegmaier, MD

Blood (2015) 126 (23): 3674.

https://doi.org/10.1182/blood.V126.23.3674.3674

Published: 2015

Journal Articles

Pharmacokinetic Profile and Pharmacodynamic Effects of ASP2215, a Selective, Potent Inhibitor of FLT3/AXL, in Patients with Relapsed or Refractory Acute Myeloid Leukemia: Results from a First-in-Human Phase 1/2 Study

Catherine C. Smith, MD, Mark J. Levis, MD PhD, Mark R Litzow, MD, Alexander E. Perl, MD, Jessica K. Altman, MD, Stanley C. Gill, PhD, Takeshi Kadokura, PhD, Geoffrey J. Yuen, Pharm.D., Ogert Fisniku, MS, Charles Liu, PhD, Itsuro Nagase, PhDDVM, Briana Sargent, BS, Noreen Welter, RN, BSN, Erkut Bahceci, MD

Blood (2015) 126 (23): 4836.

https://doi.org/10.1182/blood.V126.23.4836.4836

Published: 2015

Journal Articles

Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

Vikas Gupta, MD FRCP, FRCPath, Claire N. Harrison, Hans Hasselbalch, MD, Lisa Pieri, MD PhD, Steffen Koschmieder, MD, Francisco Cervantes, Weichao Bao, PhD, Stacey Kalambakas, MD, Edric Atienza, MSHS, Prashanth Gopalakrishna, MBBS, MRCS, Florian H. Heidel, MD

Blood (2015) 126 (23): 825.

https://doi.org/10.1182/blood.V126.23.825.825

Published: 2015

Journal Articles

Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia

Saroj Vadhan-Raj, MD, Rafat Abonour, Jonathan W. Goldman, MD, David A. Smith, MD, Christopher A. Slapak, MD, Ramon V. Tiu, MD, Xuejing Wang, Sophie Callies, Joanne Cox, Jay L. Tuttle, PhD, Yiu-Keung (James) Lau, MD PhD, Eric J. Roeland, MD

Blood (2015) 126 (23): 537.

https://doi.org/10.1182/blood.V126.23.537.537

Published: 2015

Journal Articles

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

Blood (2014) 124 (21): 291.

https://doi.org/10.1182/blood.V124.21.291.291

Published: 2014

Journal Articles

Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

Vikas Gupta, MD FRCP, FRCPath, Steffen Koschmieder, MD, Claire N. Harrison, DM, FRCP, FRCPath, Francisco Cervantes, MD PhD, Florian H Heidel, MD, Mark Drummond, MD PhD, Jerome Rey, MD, Eunju Hurh, PhD, Weichao Bao, PhD, Anita Rampersad, Stacey Kalambakas, MD, Alessandro Maria Vannucchi, MD

Blood (2014) 124 (21): 712.

https://doi.org/10.1182/blood.V124.21.712.712

Published: 2014

Journal Articles

Analysis of ROS-Responsive Genes in Mutant RAS Expressing Hematopoietic Progenitors Identifies the Glycolytic Pathway As a Major Target Promoting Both Proliferation and Survival

Goitseone Lucy Hopkins, BSc (Hons) MSc, Andrew J Robinson, BSc MRes, Paul S Hole, PhD, Richard L. Darley, BSc PhD, Alex Tonks, BSc PhD

Blood (2014) 124 (21): 2210.

https://doi.org/10.1182/blood.V124.21.2210.2210

Published: 2014

NARROW

Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study)

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma

Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas

Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study

Improving Treatment Related Mortality over Time - Data from the Non-Observational Trial on Autologous Stem Cell Transplantation in Systemic Sclerosis By the EBMT Autoimmune Diseases Working Party (ADWP)

Responses and Cardiotoxicity with R-CDOP and R-CHOP Observed in Frontline Therapy for Patients with Primary Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Randomized Phase-IV Study from Multiple Centers in China

Characterization of Cardiovascular Adverse Events and B-Type Natriuretic Peptide Levels in Patients with Multiple Myeloma Who Are Treated with Carfilzomib

Creatine Kinase Pathway Inhibition Alters GSK3 and WNT Signaling in EVI1-Positive Acute Myeloid Leukemia

Preclinical Investigation of a Potent Geranylgeranyl Diphosphate Synthase Inhibitor

Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia

Identification of CKMT1B As a New Target in EVI1-Positive AML

Pharmacokinetic Profile and Pharmacodynamic Effects of ASP2215, a Selective, Potent Inhibitor of FLT3/AXL, in Patients with Relapsed or Refractory Acute Myeloid Leukemia: Results from a First-in-Human Phase 1/2 Study

Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

Analysis of ROS-Responsive Genes in Mutant RAS Expressing Hematopoietic Progenitors Identifies the Glycolytic Pathway As a Major Target Promoting Both Proliferation and Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only